glp-1 options for type 2 diabetes and obesity 2025 What are GLP-1s? GLP-1-based therapies for type 2

SubQ technology creates a new moat to protect brand name drugs, even as underlying patents on agents expire and biosimilars are approved, because subQ technology is not universally available and new subQ co-formulation patents are being issued to protect branded drugs

Fibromyalgia and inflammation: unrevealing the connection

Research suggests that there may be differences in GLP-1 response between men and women

Intestinal tissue segments were homogenized, lysed (1 M Tris-HCl, 5 M NaCl, 1% (v/v) Igepal CA-630, 0.5% (w/v) sodium deoxycholate monohydrate, and one tablet of EDTA-free protease inhibitor cocktail), and centrifuged at 10,000 x g for 10 min to prepare the tissue extracts

These medications improve several metabolic health markers: Lower blood pressure Improved cholesterol profiles Reduced inflammation markers 8 Modest 5-7% weight loss significantly reduces type 2 diabetes risk 6